A PHASE I, OPEN-LABEL, FIXED-SEQUENCE, THREE-PERIOD CROSSOVER TRIAL TO EVALUATE THE PHARMACOKINETICS OF TWO DIFFERENT TABLET FORMULATIONS OF BCI 952 COMPARED TO THE OVER-ENCAPSULATED BCI-952 PRODUCT COMPONENTS IN HEALTHY MALE SUBJECTS - BCI-952 three-period crossover bioequivalence study
An Open-Label Extension Study to Assess the Tolerability of BCI-024 in Combination With BCI-049 in Patients With Major Depressive Disorder
The objective of this study is to allow patients who have participated in the precursor study of BCI-024 in combination with BCI-049 versus placebo or BCI-024 alone (Protocol #CBM-IT-01) to receive 6 weeks of open-label treatment with an increased dose of BCI-024 in combination with an increased dose of BCI-049.
The safety and tolerability of this higher dose of the combination will be evaluated, as will the treatment effect in reducing symptoms of depression in patients with MDD.
100 项与 盐酸丁螺环酮/褪黑素 相关的临床结果
100 项与 盐酸丁螺环酮/褪黑素 相关的转化医学
100 项与 盐酸丁螺环酮/褪黑素 相关的专利(医药)
100 项与 盐酸丁螺环酮/褪黑素 相关的药物交易